Precision biosciences inc stock.

DURHAM, N.C., November 28, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, …Get the latest Precision BioSciences, Inc. (DTIL) stock news and headlines to help you in your trading and investing decisions.Precision BioSciences, Inc. (DTIL) Stock Price, Quote, News & Analysis DTIL Precision BioSciences, Inc. Stock Price & Overview $0.37 0.0099 ( +2.79%) 3:59 …May 9, 2023 · The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc. Jun 20, 2023 · Precision Biosciences Inc (US:DTIL) has 116 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 42,897,221 shares.

Nov 29, 2023

Avidity Biosciences Inc (NASDAQ:RNA) shares are trading higher Wednesday after the company announced positive data demonstrating the fir... Avidity Biosciences Inc (NASDAQ:RNA) shares are trading higher Wednesday after the company...Individuals with disabilities: if you are a qualified individual with a disability and are unable or limited in your ability to use or access the online application system process due to your disability, please contact our disability applications assistant at 919-314-5512 to request assistance. Precision BioSciences provides reasonable ...

A high-level overview of Cogent Biosciences, Inc. (COGT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Precision BioSciences last posted its earnings results on November 7th, 2023. The reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The business earned $13.12 million during the quarter, compared to the consensus estimate of $7.50 million.Precision BioSciences to Report Third Quarter Results on November 7, 2023. DURHAM, N.C., November 01, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it will publish ... CAMBRIDGE, Mass., Oct. 5, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biotechnology company focused on developing precision therapies for genetically defined diseases ...DURHAM, N.C., November 07, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in ...

Overall, Precision BioSciences Inc stock has a Value Grade of C, Growth Grade of C, Quality Grade of D, Momentum Grade of F Earnings Estimate Revisions Grade of C. Whether or not you should buy Precision BioSciences Inc stock will ultimately depend on your individual goals, risk tolerance and allocation. AAII can help you figure …Web

Corporate Profile Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary …

Precision BioSciences Inc stock price live 0.2969, this page displays NASDAQ DTIL stock exchange data. View the DTIL premarket stock price ahead of the market session or assess the after hours quote.Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in …We note from Precision Biosciences Inc’s average daily trading volume that its 10-day average is 1.36 million shares, with the 3-month average coming to 1.15 million. Precision Biosciences Inc stock received a consensus recommendation rating of an Overweight, based on a mean score of 1.50.Discover historical prices for DTIL stock on Yahoo Finance. View daily, weekly or monthly format back to when Precision BioSciences, Inc. stock was issued. We note from Precision Biosciences Inc’s average daily trading volume that its 10-day average is 1.36 million shares, with the 3-month average coming to 1.15 million. Precision Biosciences Inc stock received a consensus recommendation rating of an Overweight, based on a mean score of 1.50.Nov 7, 2023 · DTIL stock, the ticker symbol for Precision BioSciences Inc, had a significant increase in its price on November 7, 2023. According to data from CNN Money, the 12-month price forecasts provided by four analysts for DTIL stock have a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00.

Precision BioSciences GAAP EPS of -$0.46 misses by $0.05, revenue of $3.82M misses by $1.29M SA News Mon, Aug. 08, 2022 Precision BioSciences Q2 2022 Earnings Preview22 thg 6, 2022 ... Latham & Watkins Represents Precision BioSciences in US$50 Million Offering of Common Stock ... Precision BioSciences, Inc. (Nasdaq: DTIL), a ...Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...Nov 7, 2023 · DTIL stock, the ticker symbol for Precision BioSciences Inc, had a significant increase in its price on November 7, 2023. According to data from CNN Money, the 12-month price forecasts provided by four analysts for DTIL stock have a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00. DURHAM, N.C.--(BUSINESS WIRE)--Jul. 27, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it has received final meeting minutes from its recent Type B End of Phase 1 meeting with the U.S. Food and Drug Administration (FDA) for its lead ...

Find the latest Precision BioSciences, Inc. (DTIL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Precision BioSciences has sold its lead cell therapy asset as the company shifts focus exclusively to gene editing. ... Precision's stock, for instance, closed Monday at $0.45 a share, ...Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.About the Company. Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.Given the current short-term trend, the stock is expected to fall -4.66% during the next 3 months and, with a 90% probability hold a price between $0.264 and ...As of November 28, 2023, 4:00 PM, CST, Avidity Biosciences Inc’s stock price was $7.08. Avidity Biosciences Inc is up 14.94% from its previous closing price of $6.16. During the last market session, Avidity Biosciences Inc’s stock traded between $5.97 and $6.25. Currently, there are 74.10 million shares of Avidity Biosciences Inc stock ...Precision BioSciences Announces $50 Million Offering of Common Stock. June 21, 2022 05:25 PM Eastern Daylight Time. DURHAM, N.C.-- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a ...

Stock Exchange: NASDAQ. Precision BioSciences: Culture. 233 articles about Precision BioSciences, Inc. ... Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will share an …

On November 7, 2023, Precision BioSciences Inc (DYAI) stock showed promising performances based on the information provided. According to data from CNN Money, the four analysts offering 12-month price forecasts for DYAI had a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00.

Find the latest Precision BioSciences, Inc. (DTIL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Find out why I rate DTIL stock a Buy.WebIn addition to a $25 million equity investment from Novartis in Precision’s common stock at $2.01 per share received in June 2022, Precision received an upfront cash payment of $50 million on ...The increase in weighted average shares of common stock outstanding was primarily due to a $50 million underwritten offering of common stock and Novartis’ $25 million equity investment in 2022. About Precision BioSciences, Inc.Nov 7, 2023 · Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to ... HC Wainwright Adjusts Price Target on Precision BioSciences to $3 From $5, Keeps Buy Rating. Aug. 17. MT. BMO Capital Downgrades Precision BioSciences to Market Perform From Outperform, Adjusts Price Target to $4 From $7. Mar. 14. MT. Goldman Sachs Adjusts Price Target on Precision BioSciences to $1 From $2, Maintains Neutral Rating. Nov. 10. MT.The company that owns Cummins diesel engines is Cummins Inc., a public company that is listed on the stock market. It is listed on the New York Stock Exchange, and most of its shares are owned by institutional shareholders.Yu: Precision BioSciences: Current Employment, Current equity holder in publicly-traded company. Heery: Precision BioSciences: Current equity holder in publicly-traded company, Ended employment in the past 24 months; Arcellx: Current Employment, Current holder of stock options in a privately-held company.

A high-level overview of Precision BioSciences, Inc. (DTIL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...Precision BioSciences Inc share price live 0.4366, this page displays NASDAQ DTIL stock exchange data. View the DTIL premarket stock price ahead of the …Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week. (Simply Wall St.) Jan-09-23 07:30AM. Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones.Instagram:https://instagram. best schools for stock brokersstock hubacciones que pagan dividendoshow to tell if penny is steel Nov 24, 2023 · With Precision Biosciences stock trading at $0.41 per share, the total value of Precision Biosciences stock (market capitalization) is $49.24M. Precision Biosciences stock was originally listed at a price of $17.44 in Mar 28, 2019. If you had invested in Precision Biosciences stock at $17.44, your return over the last 4 years would have been ... A high-level overview of Precision BioSciences, Inc. (DTIL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. o realitydollar10 stocks See Precision BioSciences, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. ppl corp stock price May 9, 2023 · Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ... When you look at Precision BioSciences Inc’s price-to-sales ratio at 0.93 compared to the industry median at 6.93, this company has a lower price relative to revenue compared to its peers. This could make Precision BioSciences Inc’s stock more attractive for value investors.